AstraZeneca receives double EU recommendation for cancer drug
Lynparza is recommended for marketing authorisation for ovarian and prostate cancer, while Tagrisso showed positive results in late-stage trials for lung cancer
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 28 of 55
AstraZeneca resumes coronavirus vaccine trials in the UK
The Medicines Health Regulatory Authority has advised it was safe to restart the tests
Archive
The week in coronavirus: UK infection rate grows as AstraZeneca halts vaccine trials
A look at the week's major news regarding the pandemic
AstraZeneca to move to Nasdaq from New York Stock Exchange
The pharma giant is looking to cut costs, while it also announced “high-level” results for its rhinosinusitis candidate
AstraZeneca pauses Oxford coronavirus vaccine trial after adverse effect
The pharma giant said it is standard routine to allow review of safety data to ensure the integrity of the trials
Archive
FTSE 100 closes ahead as investors return to 'buy the dip' mode
Britain's top share index closed over 82 points higher at 6,012 midweek
Coronavirus: Australia secures two deals to roll out 85mln vaccine doses next year
Both agreements, for a UK formulation and a local one, are worth £900mln
AstraZeneca receives EU approval for Imfinzi for extensive-stage small cell lung cancer
The pharma giant also announced exceptional results for Farxiga in patients with chronic kidney disease
AstraZeneca agrees to supply 300mln COVID-19 vaccine doses to EU
The deal includes an option for a further 100 million doses
The runners in the COVID-19 vaccine race
A round-up of the most promising candidates to help immunise the world's population to end the pandemic
Oxford coronavirus vaccine potentially submitted to regulator this year, says scientist
Partner AstraZeneca has also denied discussions with US authorities for a fast-track approval
AstraZeneca kicks off in-human trial for coronavirus treatment using monoclonal antibodies
AZD7442’s combination of mAbs was derived from convalescent patients with SARS-CoV-2 infection
Archive
FTSE 100 closes in the red as hopes of a speedy vaccine are dashed
Britain's blue chip benchmark erased most of yesterday's gains to close down over 67 points at 6,037, down 1.11% on the day
Archive
Apple and tech stocks drive US markets to record highs
All three US benchmarks finished higher in New York, while Apple increase 1.2% to $503 a share
AstraZeneca says Imfinzi approved as lung cancer drug combination in Japan
In the first half of 2020, Imfinzi was one of the company's best-selling medicines, generating US$954mln of revenues
Coronavirus latest: Vaccine arm's race continues as EU holds talks with CureVac over bumper order
The EU is also in talks with Johnson & Johnson and Sanofi and has agreed advanced purchase deal with AstraZeneca for at least 300mln shots of the drug it is developing with the University of Oxford
AstraZeneca to issue debt at 0.7% interest rate
The issue is part of a three-tranche global bond offering totalling $3bn that is expected to close on 6 August.
AstraZeneca's new medicines continue to drive growth in first half
Oncology continued to be the star, growing sales 28% to US$5.3bn or 42% of total group revenue
Archive
FTSE 100 closes in the red; Wall Street struggles on grim GDP outlook
The index of UK blue-chips dropped 142 points to finish at 5,990
Archive
Coronavirus vaccines and oil dividends in focus on Thursday as AstraZeneca and Shell update investors
AstraZeneca, Shell and Lloyds are among the notable names in Thursday's diary.